Skip to main content

Table 1 Patient characteristics and sub-volume data

From: Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study

Dog no.

Tumor type

Tumor localization

GTV (ccm)

FDG40 (ccm)

FDG50 (ccm)

Cu3 (ccm)

Cu24 (ccm)

Cu3FDG40 (ccm)

Cu3FDG50(ccm)

Cu3∩FDG40/FDG40 (%)

Cu3∩FDG40/Cu3 (%)

Cu3∩FDG50/FDG50 (%)

Cu3∩FDG50/Cu3 (%)

1

Hemangiopericytoma

Lumbar region

128.7

13.0

3.4

85.8

61.6

86.1

85.9

98.5

14.9

98.2

3.9

2

Fibrosarcoma

Lat. cervical region

88.2

66.4

60.1

63.9

17.0

73.9

71.3

84.7

88.4

88.2

82.8

3

Squamous cell carcinoma

Nasal cavity

55.4

23.7

17.0

21.2

30.0

28.7

25.4

68.9

76.9

76.4

61.0

4

Adenocarcinoma

Nasopharynx

20.8

10.3

5.3

9.3

3.5

13.0

10.7

62.9

69.3

75.4

42.8

5

Undiff. soft tissue sarcoma

Mandible

23.2

11.2

8.4

6.2

0.6

12.2

10.2

46.6

83.9

52.8

70.8

Avg.

  

63.3

24.9

18.8

37.3

22.5

42.8

40.7

72.3

66.7

78.2

52.3